Novo Nordisk/$NVO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Employees
78,387
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk Metrics
BasicAdvanced
$216B
12.56
$3.84
0.27
$1.23
1.71%
Price and volume
Market cap
$216B
Beta
0.27
52-week high
$110.30
52-week low
$45.05
Average daily volume
13M
Dividend rate
$1.23
Financial strength
Current ratio
0.784
Quick ratio
0.505
Long term debt to equity
51.947
Total debt to equity
59.065
Dividend payout ratio (TTM)
45.63%
Interest coverage (TTM)
17.27%
Profitability
EBITDA (TTM)
24,511.861
Gross margin (TTM)
84.26%
Net profit margin (TTM)
35.61%
Operating margin (TTM)
47.65%
Effective tax rate (TTM)
21.10%
Revenue per employee (TTM)
$612,560
Management effectiveness
Return on assets (TTM)
21.82%
Return on equity (TTM)
79.17%
Valuation
Price to earnings (TTM)
12.563
Price to revenue (TTM)
4.469
Price to book
8.33
Price to tangible book (TTM)
23.27
Price to free cash flow (TTM)
22.631
Free cash flow yield (TTM)
4.42%
Free cash flow per share (TTM)
2.132
Dividend yield (TTM)
2.55%
Forward dividend yield
1.71%
Growth
Revenue change (TTM)
20.90%
Earnings per share change (TTM)
24.26%
3-year revenue growth (CAGR)
25.65%
10-year revenue growth (CAGR)
12.15%
3-year earnings per share growth (CAGR)
31.20%
10-year earnings per share growth (CAGR)
15.33%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Bulls say / Bears say
Novo Nordisk delivered a Q1 operating profit of DKK 38.79 billion, up 22% year-over-year and beating expectations, highlighting robust cost management and the continued strength of its diabetes and obesity franchises. (Reuters)
The company’s unsolicited $8.5 billion bid to acquire Metsera accelerates its pipeline diversification by adding promising GLP-1 injectable MET-097i and amylin analog MET-233i, shoring up long-term growth prospects beyond its existing semaglutide portfolio. (Reuters)
Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics extends its reach into metabolic dysfunction-associated steatohepatitis (MASH) with the Phase 3 drug efruxifermin, reducing reliance on weight-loss treatments and broadening its therapeutic footprint. (Financial Times)
Novo Nordisk has twice cut its full-year 2025 guidance, now expecting sales to grow just 8–14% and operating profit 10–16% at constant exchange rates, underscoring a slowdown in demand for its flagship GLP-1 drugs amid market saturation and competitive pressures. (Reuters)
Q1 sales of Wegovy fell 13% sequentially to DKK 17.36 billion, missing analyst forecasts and reflecting stagnating U.S. prescriptions as compounded alternatives and rival therapies undercut Novo Nordisk’s market leadership. (Reuters)
Novo Nordisk will cut 9,000 jobs—11% of its workforce—to save DKK 8 billion annually, a move that could impair commercial execution and R&D momentum just as competition intensifies in the obesity and diabetes markets. (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk
WSJ6 hours ago
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
Investopedia11 hours ago
Novo Nordisk slashes full-year sales forecast amid competition in diabetes and obesity markets
Proactive Investors11 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $216B as of November 06, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 12.56 as of November 06, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $1.23062 and the yield is 1.71%. Novo Nordisk has a payout ratio of 45.63% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.